SCHEMBL23728698

SCHEMBL23728698

CC(C)(C)OC(=O)NCCCN(CCCNC(=O)OCc1ccccc1)CC(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
HTT P42858 1/20 0.51
SYK P43405 1/20 0.50
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
IDO1 P14902 1/20 0.47
TGM2 P21980 1/20 0.46
KEAP1 Q14145 3/20 0.46
NFE2L2 Q16236 3/20 0.46
KLK7 P49862 2/20 0.45
KLK5 Q9Y337 2/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
POLB P06746 1/20 0.43
MAPK1 P28482 1/20 0.43
FOLH1 Q04609 1/20 0.43
SIGMAR1 Q99720 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16789588 0.91 HTT (0.58) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL29248526 0.89 HTT (0.55) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL29924885 0.88 HTT (0.54) MAPTHTTLMNASMN1; SMN2TGM2
SCHEMBL29924523 0.86 HTT (0.50) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL30533303 0.85 MAPT (0.52) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL13480435 0.85 MAPT (0.65) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL13938297 0.85 HTT (0.65) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL15613432 0.84 SYK (0.58) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL31165330 0.84 SYK (0.58) MAPTHTTSYKLMNASMN1; SMN2
SCHEMBL15679441 0.84 MAPT (0.64) MAPTHTTSYKLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360105-A1 PROCESS FOR POLYAMIDE SYNTHESIS Design Therapeutics, Inc. 2024-10-31 US disclosed
EP-4384506-A1 PROCESS FOR POLYAMIDE SYNTHESIS Design Therapeutics, Inc. (US) 2024-06-19 EP disclosed
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2024-02-15 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
CN-115768765-A Methods and compounds for treating genetic diseases 设计治疗公司 2023-03-07 CN disclosed
WO-2023014793-A1 PROCESS FOR POLYAMIDE SYNTHESIS Design Therapeutics, Inc. (US) 2023-02-09 WO disclosed
EP-4100404-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158707-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP MAPT 946/4885HTT 32/4885SYK 4851/4885
US-20240360105-A1 PROCESS FOR POLYAMIDE SYNTHESIS POLI, POLR2A, POLR2B MAPT 3594/4885HTT 2078/4885SYK 3464/4885
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, GRN, F13B MAPT 3053/4885HTT 53/4885SYK 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.